Transcription of American Thoracic Society Documents
{{id}} {{{paragraph}}}
Example: stock market
American Thoracic Society Documents
American Thoracic Society DocumentsAn Official American Thoracic Society Statement:Treatment of Fungal Infections in Adult Pulmonaryand Critical Care PatientsAndrew H. Limper, Kenneth S. Knox, George A. Sarosi, Neil M. Ampel, John E. Bennett, Antonino Catanzaro,Scott F. Davies, William E. Dismukes, Chadi A. Hage, Kieren A. Marr, Christopher H. Mody, John R. Perfect,and David A. Stevens, on behalf of the American Thoracic Society Fungal Working GroupTHISOFFICIALSTATEMENT OF THEAMERICANTHORACICSOCIETY(ATS)WAS APPROVED BY THEATS BOARDOFDIRECTORS,MAY2010 CONTENTSI ntroductionMethodsAntifungal Agents: General ConsiderationsPolyenesTriazolesEchinocan dinsTreatment of Fungal InfectionsHistoplasmosisSporotrichosisBl astomycosisCoccidioidomycosisParacoccidi oidomycosisCryptococcosisAspergillosisCa ndidiasisPneumocystis PneumoniaTreatment of Other FungiGlossary of TermsWith increasing numbers of immune-compromised patients withmalignancy,hematologicdisease,andHIV ,aswellasthosereceivingimmunosupressive drug regimens for the management of organtransplantation or autoimmune inflammatory conditions, the in-cidence of fungal infections has dramatically increased over recentyears.
concomitant nephrotoxic drugs. For diseases where dosing of amphotericin B at 1.0 mg/kg/day or higher is standard, the intrinsic nephrotoxicity of amphotericin B itself dictates pre-ferreduseoflipidformulations.AswithstandardamphotericinB formulations, monitoring for side effects during therapy should
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: